This site is intended for US healthcare professionals only.

First FDA-approved therapy in nearly 30 years for locally advanced pancreatic cancer (LAPC)1,2

Optune Pax® with gemcitabine and nab-paclitaxel (gem/nab-pac) vs gem/nab-pac*:

Significantly extended overall survival1,2

mOS in the ITT population†:

  • 16.2 months (95% CI: 15.0–18.0) vs 14.2 months (95% CI: 12.8–15.4)

mOS in the mPP population‡:

  • 18.3 months (95% CI: 16.1–20.0) vs 15.1 months (95% CI: 13.4–17.0)
Explore the clinical data

Delayed pain progression1

Median time to pain progression§:

  • 15.2 months (95% CI: 10.3–22.8) vs 9.1 months (95% CI: 7.4–12.7)
Explore the clinical data

Did not exacerbate systemic toxicities1-3

The majority of device-related AEs were skin AEs, observed in 76.3% of patients; the majority of skin AEs were mild to moderate

Explore the clinical data

Optune Pax was studied in PANOVA-3, a phase 3, open-label, randomized study evaluating the safety and efficacy of Optune Pax concomitant with gem/nab-pac in patients with LAPC (N=571)1

  • Patients were randomized 1:1 to receive either Optune Pax with gem/nab-pac or gem/nab-pac alone1
  • Primary endpoint: Overall survival with Optune Pax and gem/nab-pac vs gem/nab-pac alone1

*A statistically significant difference in the OS distribution between study arms was observed. ITT population: HR: 0.82; 95% CI: 0.68–0.99; P=0.039; mPP population: HR: 0.77; 95% CI: 0.62–0.97; P=0.023.

†PANOVA-3 was a global, randomized, open-label, phase 3 trial (N=571) of patients with locally advanced pancreatic cancer. The trial included patients with unresectable LAPC who had histological or cytological diagnosis, ECOG PS 0–2, and no other concurrent anticancer treatment. Patients were randomized 1:1 to receive treatment with either Optune Pax with gem/nab-pac or gem/nab-pac alone. The primary endpoint was overall survival in the Intent-to-Treat population.  Follow-up was performed every 4 weeks. Optune Pax treatment continued until local disease progression, death, or unacceptable device-related adverse events. Chemotherapy continued until disease progression, death, or unacceptable toxicity.

‡The mPP population includes only those patients who received at least 1 cycle of gem/nab-pac (both arms) and, for the Optune Pax with gem/nab-pac arm, also received at least 4 weeks (28 days) of TTFields therapy.

§Patients who experienced local disease progression were no longer followed for pain progression (67/285 patients in the Optune Pax with gem/nab-pac arm and 56/286 patients in the gem/nab-pac arm). Because a large number of patients stopped pain assessments after local disease progression, this censoring approach can lead to an overestimation.

Optune Pax delivers TTFields, which disrupt processes critical for cancer cell division and survival2,4

Learn how it works

Is Optune Pax right for your patients with LAPC?

Learn about eligibility

Proactive skincare management is important while using Optune Pax

See tips for management

AE=adverse event; CI=confidence interval; FDA=US Food and Drug Administration; HR=hazard ratio; ITT=intent-to-treat; mPP=modified per protocol; mOS=median overall survival; TTFields=Tumor Treating Fields.

 

 

 

References: 1. Optune Pax for Locally Advanced Pancreatic Cancer (LAPC). Physician Instructions for Use. Novocure; 2026. 2. Babiker HM, Picozzi V, Chandana SR, et al. Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase III PANOVA-3 study. J Clin Oncol. 2025;43(21):2350-2360. doi:10.1200/JCO-25-00746 3. Novocure Data on File 2025. [EF-27 (PANOVA-3) Clinical investigation report.] 4. Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol. 2021;97(8):1044-1054. doi:10.1080/09553002.2020.1837984

 

 

Indication for Use

Optune Pax® is intended for the treatment of adult patients with locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.

Important Safety Information

Contraindications

Do not use Optune Pax in patients with an electrical implant. Use of Optune Pax together with electrical implants has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Pax in patients with a known sensitivity to conductive hydrogels. In patients with this sensitivity, skin contact with the gel used with Optune Pax may commonly cause increased redness and itching. In rare cases, it may lead to severe allergic reactions that can cause a drop in blood pressure and difficulty breathing.

Warnings and Precautions

Optune Pax can only be prescribed by a healthcare provider who has completed the required certification training provided by Novocure® (the device manufacturer).

Do not prescribe Optune Pax for patients who are pregnant, who you think might be pregnant, or who are trying to get pregnant. Women who are able to get pregnant must use birth control when using the device. Safety and effectiveness of Optune Pax in these populations have not been established.

The most common (≥10%) adverse events involving Optune Pax concomitant with gemcitabine and nab-paclitaxel were neutropenia, anemia, thrombocytopenia, leukopenia, diarrhea, nausea, vomiting, abdominal pain, constipation, fatigue, peripheral edema, pyrexia, pain, COVID-19, infection, respiratory tract infection, urinary tract infection, pneumonia, hepatic enzyme increased, anorexia, hypokalemia, hypoalbuminemia, hyperglycemia, musculoskeletal pain, peripheral neuropathy, taste disorder, dizziness, sleep disorder, dyspnea, alopecia, skin-related disorders, and hypotension.

Optune Pax device-related skin adverse events (≥5%) include dermatitis, rash, pruritus, maculo-papular rash, erythema, skin irritation, skin reaction, and skin ulcer. Other device-related adverse effects associated with the use of Optune Pax include overheating of the array, leading to pain and/or local skin burns, allergic reaction to the adhesive or gel from the transducer arrays, and local warmth and tingling sensation beneath the arrays.

If the patient has an underlying skin condition on the abdomen, evaluate whether this may prevent or temporarily interfere with Optune Pax treatment.

Please see the Optune Pax Instructions for Use (IFU) for complete information regarding the device’s indication, contraindications, warnings, and precautions.

 

Indication for Use

Optune Pax® is intended for the treatment of adult patients with locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.

Important Safety Information

Contraindications

Do not use Optune Pax in patients with an electrical implant. Use of Optune Pax together with electrical implants has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Pax in patients with a known sensitivity to conductive hydrogels. In patients with this sensitivity, skin contact with the gel used with Optune Pax may commonly cause increased redness and itching. In rare cases, it may lead to severe allergic reactions that can cause a drop in blood pressure and difficulty breathing.

Warnings and Precautions

Optune Pax can only be prescribed by a healthcare provider who has completed the required certification training provided by Novocure® (the device manufacturer).

Do not prescribe Optune Pax for patients who are pregnant, who you think might be pregnant, or who are trying to get pregnant. Women who are able to get pregnant must use birth control when using the device. Safety and effectiveness of Optune Pax in these populations have not been established.

The most common (≥10%) adverse events involving Optune Pax concomitant with gemcitabine and nab-paclitaxel were neutropenia, anemia, thrombocytopenia, leukopenia, diarrhea, nausea, vomiting, abdominal pain, constipation, fatigue, peripheral edema, pyrexia, pain, COVID-19, infection, respiratory tract infection, urinary tract infection, pneumonia, hepatic enzyme increased, anorexia, hypokalemia, hypoalbuminemia, hyperglycemia, musculoskeletal pain, peripheral neuropathy, taste disorder, dizziness, sleep disorder, dyspnea, alopecia, skin-related disorders, and hypotension.

Optune Pax device-related skin adverse events (≥5%) include dermatitis, rash, pruritus, maculo-papular rash, erythema, skin irritation, skin reaction, and skin ulcer. Other device-related adverse effects associated with the use of Optune Pax include overheating of the array, leading to pain and/or local skin burns, allergic reaction to the adhesive or gel from the transducer arrays, and local warmth and tingling sensation beneath the arrays.

If the patient has an underlying skin condition on the abdomen, evaluate whether this may prevent or temporarily interfere with Optune Pax treatment.

Please see the Optune Pax Instructions for Use (IFU) for complete information regarding the device’s indication, contraindications, warnings, and precautions.

 

Novocure websites

This website is intended for US healthcare professionals seeking information on Optune Pax.

©2026 Novocure GmbH. All Rights Reserved.

Optune Gio, Optune Lua, Optune Pax, MyLink, MyNovocure, and Novocure are registered trademarks of Novocure GmbH.

All other trademarks, registered or unregistered, are the property of their respective owners.

US-OPP-00007 v1.0 March 2026